Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.53 |
| ▸ | DRD3 | P35462 | 12/20 | 0.53 |
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204338 | 0.88 | HTR6 (0.55) | HTR6DRD3DRD2HTR1AHTR2A | |
| SCHEMBL6179546 | 0.87 | HTR6 (0.43) | HTR6DRD3DRD2HRH3 | |
| SCHEMBL5204216 | 0.83 | GPR119 (0.43) | HTR6 | |
| Tert-Butyl Formate SCHEMBL27641072 | 0.81 | HTR6 (0.45) | HTR6DRD3DRD2HTR1AHTR2A | |
| SCHEMBL14163710 | 0.74 | HTR6 (0.54) | HTR6DRD3DRD2HTR1AHTR2A | |
| SCHEMBL6190107 | 0.69 | HTR6 (0.51) | HTR6HTR1AHTR2CHTR7 | |
| SCHEMBL6188544 | 0.69 | HTR6 (0.44) | HTR6DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15311895 | 0.68 | DRD2 (0.46) | HTR6DRD3DRD2HTR1AHTR2A | |
| SCHEMBL17765857 | 0.68 | F11 (0.55) | — | |
| SCHEMBL5200724 | 0.67 | HTR6 (0.81) | HTR6DRD3DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601358-B1 | 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | claimed |
| US-7196088-B2 | Substituted tetrahydroisoquinolines and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | claimed |
| EP-1601358-A1 | 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-07 | — | — | EP | claimed |
| US-20040180874-A1 | Substituted tetrahydroisoquinolines and uses thereof | ROCHE PALO ALTO LLC | 2004-09-16 | — | — | US | claimed |
| WO-2004078176-A1 | 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-16 | — | — | WO | claimed |
| CN-100395237-C | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators | ROCHE PALO ALTO LLC (CH) | 2008-06-18 | — | — | CN | disclosed |
| EP-1601358-B1 | 2,5-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7196088-B2 | Substituted tetrahydroisoquinolines and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| CN-1756550-A | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators | ROCHE PALO ALTO LLC (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1601358-A1 | 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-07 | — | — | EP | disclosed |
| US-20040180874-A1 | Substituted tetrahydroisoquinolines and uses thereof | ROCHE PALO ALTO LLC | 2004-09-16 | — | — | US | disclosed |
| WO-2004078176-A1 | 2,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180874-A1 | Substituted tetrahydroisoquinolines and uses thereof | CYP3A5, CYP4X1, UGT1A1 | HTR6 1252/4885DRD3 291/4885DRD2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.